Teva Branded Pharmaceutical Products R&D Inc., Malvern, PA. RATIONALE: Reslizumab, a humanized anti-interleukin-5 monoclonal antibody, improves asthma exacerbation rates, lung function, and patientreported outcomes in patients with inadequately controlled eosinophilic asthma. This post-hoc analysis explored EOS levels and lung function among patients with low FEV 1 REV to SABA. METHODS: Data were pooled from two 52-week placebo-controlled trials of IV reslizumab 3mg/kg (Q4wks) in patients with screening EOS > _400mL and REV > _12% to SABA. REV by baseline (day of first dose) EOS category and lung function treatment effect in the lowest-REV/highest-EOS group were analyzed. RESULTS: Patients (N5953) were categorized by baseline EOS <150 (n565), 150-<400 (n5179), 400-<700 (n5365), and > _700/mL (n5344) and by baseline REV <14% (n5149), 14-<20% (n5276), and > _20% (n5528). Patients with higher EOS levels showed trends towards lower mean REV and a higher proportion with REV <14% versus patients with lower EOS levels (EOS > _700: mean6SE %REV 24.761.4, 17% with REV <14%, 52% with REV > _20%; EOS <150: 28.562.5, 12% with REV <14%, 60% with REV > _20%). Treatment effects at 52 weeks (reslizumab vs placebo) in the low REV (<14%) group, pooled two highest EOS categories (> _700, 400-<700) were: FEV 1 168mL (95% CI: 4-332), %pre-dicted FEV 1 6.2% (1.1-11.2%), FVC 144mL (-62-350) , and FEV 25-75% 131mL (-96-357) . CONCLUSIONS: Higher blood EOS is associated with lower FEV 1 REV in inadequately controlled eosinophilic asthma. Reslizumab treatment results in clinically significant improvements in lung function outcomes in patients with high EOS and low REV. Reslizumab may reverse relatively ''fixed'' airway obstruction in these patients.
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Eosinophil progenitor cell blood levels inversely correlate with disease control in pediatric patients with asthma Justin T. Schwartz, MD PhD, Adam Z. Magier, BS, Sarah A. Marshall, BS, and Patricia C. Fulkerson, MD PhD; Cincinnati Children's Hospital Medical Center, Cincinnati, OH. RATIONALE: Eosinophil progenitors (EoPs) are eosinophil lineagecommitted, CD34+ progenitor cells that primarily reside in the bone marrow. Growing evidence demonstrates these cells are mobilized into the peripheral blood during allergic responses. We investigated whether EoP levels were increased in patients with asthma and whether they correlated with disease severity and asthma control. METHODS: Pediatric patients (6-18 years) with severe eosinophilic asthma (n58), mild allergic asthma (n510) and non-atopic controls (n59) were recruited. Asthma Control Test (ACT) scores, absolute eosinophil counts (AEC) and immunoglobulin E (IgE) levels were obtained at enrollment. Total CD34
High cells and EoPs were quantified in the blood by flow cytometry. Data are expressed as the mean ratio of CD34 High or EoP count per 1x10 6 lymphocyte gate events 6SD. Statistical analyses were completed with one-way ANOVA with post hoc comparisons using Tukey's multiple comparison's test and Spearman correlations.
RESULTS: Whereas the CD34
High population did not differ among groups, EoP levels were significantly increased (P50.01) in the peripheral blood of patients with mild asthma (36.7614.3) compared to controls (19.5610.5). EoP levels were also elevated in patients with severe eosinophilic asthma (27614.3), although the difference compared to controls was not significant. Notably, EoP levels inversely correlated with asthma control as assessed by ACT scores (r s 50.58, P50.015), but did not correlate with AEC or IgE levels. CONCLUSIONS: These data suggest that EoP cells are specifically mobilized into the peripheral blood of pediatric patients with asthma. Lower EoP levels may be associated with loss of asthma control, potentially via recruitment of these cells into the tissue.
